Cargando…

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy

Encorafenib plus binimetinib combination therapy is one of the first-line therapies for advanced melanoma, and it is known to cause a different profile of adverse events (AEs) than dabrafenib plus trametinib combination therapy. Of such AEs, tubulointerstitial nephritis caused by BRAF plus MEK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kambayashi, Yumi, Ohuchi, Kentaro, Chiba, Hiromu, Tamabuchi, Erika, Nagasawa, Tasuku, Asano, Yoshihide, Fujimura, Taku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149537/ https://www.ncbi.nlm.nih.gov/pubmed/35702675 http://dx.doi.org/10.1159/000524013

Ejemplares similares

Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019)

Quantitative Analysis of Immune-Reactive Cells among Leukocytes Is Useful for the Diagnosis of Drug Eruptions Caused by Bexarotene
por: Chiba, Hiromu, et al.
Publicado: (2022)

CD25 expression could be a prognostic marker of bexarotene monotherapy for cutaneous T‐cell lymphomas
por: Yamamoto, Jun, et al.
Publicado: (2023)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

Matrix Metalloproteinase 28-Bearing Microcystic Adnexal Carcinoma on the Back
por: Chiba, Hiromu, et al.
Publicado: (2021)

Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma
por: Seethapathy, Harish, et al.
Publicado: (2020)

Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases
por: Ohuchi, Kentaro, et al.
Publicado: (2022)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib
por: Gravbrot, Nicholas, et al.
Publicado: (2019)

Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
por: Augustyn, Kourtney, et al.
Publicado: (2023)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020)

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab
por: Amagai, Ryo, et al.
Publicado: (2023)

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy
por: Issac, Aaron G., et al.
Publicado: (2022)

LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages
por: Ohuchi, Kentaro, et al.
Publicado: (2023)

Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
por: Ohuchi, Kentaro, et al.
Publicado: (2021)

Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy
por: Sun, James, et al.
Publicado: (2018)

Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines
por: Patel, Vikas, et al.
Publicado: (2021)

Treatment of Advanced Melanoma: Past, Present and Future
por: Fujimura, Taku, et al.
Publicado: (2020)

Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
por: Amagai, Mayuko, et al.
Publicado: (2022)

Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
por: Fujimura, Taku, et al.
Publicado: (2020)

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
por: Boccaccino, A., et al.
Publicado: (2022)

Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/− binimetinib or alpelisib
por: Huijberts, Sanne C. F. A., et al.
Publicado: (2020)

Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022)

Pigmented Epithelioid Melanocytoma (Animal Types of Melanoma) on the Nose
por: Ohuchi, Kentaro, et al.
Publicado: (2018)

Metastatic PRAME-Expressing Juvenile Spitzoid Melanoma on the Buttock
por: Muto, Yusuke, et al.
Publicado: (2020)

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2021)

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
por: Kopetz, S., et al.
Publicado: (2022)

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Houten, Rachel, et al.
Publicado: (2020)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Severe Demyelinating Neuropathy in an Advanced Melanoma Patient Treated with Nivolumab plus Ipilimumab Combined Therapy
por: Kambayashi, Yumi, et al.
Publicado: (2020)

Acute tubulointerstitial nephritis induced by checkpoint inhibitors versus classical acute tubulointerstitial nephritis: are they the same disease?
por: Draibe, Juliana B, et al.
Publicado: (2020)

Hypocomplementaemic immune complex tubulointerstitial nephritis
por: Gupta, Alok, et al.
Publicado: (2010)

Tubulointerstitial Nephritis Associated with Enteritis and Sacroiliitis
por: Ushimaru, Shu, et al.
Publicado: (2018)

Tubulointerstitial lesions converted into lupus nephritis
por: Yang, Ning, et al.
Publicado: (2019)

Immunotherapy-Induced Acute Tubulointerstitial Nephritis
por: Parza, Kevin, et al.
Publicado: (2021)

Acute tubulointerstitial nephritis and COVID-19
por: Ng, Jia H, et al.
Publicado: (2021)

Tubulointerstitial nephritis and uveitis in Northern Ireland
por: Heaney, A., et al.
Publicado: (2021)

Crosstalk between regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs) during melanoma growth
por: Fujimura, Taku, et al.
Publicado: (2012)

Tubulointerstitial nephritis and uveitis syndrome in an elderly woman
por: Abdelghany, Mahmoud, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ui1k14ne1kc09or0brkorsc1n4